£2.0M
Deepbridge Capital provides follow-on funding to accelerate preclinical pipelines and targeted therapies.
Elasmogen
Elasmogen develops next generation biologics and soloMER therapeutics for targeted disease treatment.
£2.0MTotal raised
Elasmogen is a biopharmaceutical company developing next generation biologics known as soloMERs for site-specific drug delivery. The firm originates from research at the University of Aberdeen and focuses on treatments for inflammatory conditions and oncology.
Categories
Team
Caroline Barelle
CEO
Caroline is the chief executive officer and founder of Elasmogen and sits on the Scottish Technology Council. She also serves as a board member for Opportunity North East and the Medicines Manufacturing Innovation Centre.
LinkedIn